Sun Pharma Advanced Research Company Limited — Board Meeting, 18-05-2026: Outcome of Board Meeting

SPARC's Board approved Q4 & FY26 consolidated financial results. Net profit surged to ₹1761.34 Cr for Q4 & ₹1553.20 Cr for the year, primarily driven by ₹1840.02 Cr income from a USFDA Priority Review Voucher (PRV) for Sezaby®, later sold for $195 million.